![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
Sponsored by: |
ThromboGenics |
---|---|
Information provided by: | ThromboGenics |
ClinicalTrials.gov Identifier: | NCT00123266 |
The purpose of the trial is to evaluate the safety of microplasmin as well as its ability to open blocked arteries to the brain in patients with acute stroke when given into the artery at the site of the blockage.
Condition | Intervention | Phase |
---|---|---|
Stroke |
Drug: Microplasmin |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Official Title: | An Open-Label, Clinical Trial of Intra-Arterial Microplasmin Administration in Patients With Acute Intracranial Vertebrobasilar Artery Occlusion |
Enrollment: | 2 |
Study Start Date: | December 2006 |
Study Completion Date: | August 2008 |
Primary Completion Date: | July 2007 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental |
Drug: Microplasmin
2 mg/kg, IA over 75 mins
|
Patients with angiographically documented acute intracranial vertebrobasilar artery occlusion presenting within 24 hours of neurological symptom onset will be enrolled into this open-label trial. During study drug administration, angiograms will be repeated at regular intervals to determine degree of clot lysis.
Ages Eligible for Study: | 18 Years to 75 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Germany | |
HSK Dr. Horst Schmidt Hospital | |
Wiesbaden, Germany, 65199 | |
Ludwig-Maximilians-University Hospital | |
Munich, Germany | |
Universitätsklinikum des Saarlandes | |
Homburg/Saar, Germany, 66421 | |
Universitätsklinikum Erlangen | |
Erlangen, Germany, D-91054 | |
UKSH Campus Kiel | |
Kiel, Germany, 24105 | |
Universitatsklinikum Freiburg | |
Freiburg, Germany, D-79106 | |
Netherlands | |
Sint Antonius Ziekenhuis | |
Nieuwegein, Netherlands, 3430 EM |
Principal Investigator: | Gerhard Hamann, Prof. Dr | HSK Dr. Horst Schmidt Hospital |
Responsible Party: | ThromboGenics ( Saskia Cremers ) |
Study ID Numbers: | TG-M-003 |
Study First Received: | July 21, 2005 |
Last Updated: | November 25, 2008 |
ClinicalTrials.gov Identifier: | NCT00123266 History of Changes |
Health Authority: | Germany: Federal Institute for Drugs and Medical Devices; Netherlands: The Central Committee on Research Involving Human Subjects (CCMO) |
stroke vertebrobasilar basilar Acute vertebrobasilar artery occlusion |
Cerebral Infarction Stroke Vascular Diseases |
Central Nervous System Diseases Brain Diseases Cerebrovascular Disorders |
Nervous System Diseases Stroke Vascular Diseases Central Nervous System Diseases |
Cardiovascular Diseases Brain Diseases Cerebrovascular Disorders |